TRODELVY in Pretreated HR+/HER2- mBC and mTNBC
Loading Map....
Join your colleagues for an educational program!
The presenter will discuss key information for TRODELVY in HR+/HER2-negative mBC and mTNBC, including clinical trial data, safety, dosing, and more.
When: Wednesday, March 5th at 6:00 PM
Presented by: Fengting Yan, MD, Medical Oncologist, True Family Women’s Cancer Center Swedish Cancer Institute
Where: Le Papillon, 410 Saratoga Ave, San Jose, CA 95129
RSVP: Please RSVP via email or phone by 3/2/2025.
Tim Cochrane – tim.cochrane@gilead.com, 408-487-9857
Eric Miller – eric.miller3@gilead.com, 925-487-9857
Peter Comeau – peter.comeau@gilead.com, 925-785-7043
